How does Trump's 'most-favoured-nation' (MFN) pricing policy affect Eli Lilly's obesity drug launch plans in Europe?

Trump's 'most-favoured-nation' (MFN) pricing policy—under which Lilly committed to provide MFN pricing on new medicines—will influence all of its upcoming launches, including in Europe and Britain; specifically, Lilly plans to seek reimbursed prices consistent with its interpretation of the MFN framework, which links prices to U.S. net prices adjusted for countries' income levels, and while the company still aims for public coverage wherever possible, the MFN policy introduces uncertainty into negotiations with European health authorities.

What is Eli Lilly's go-to-market strategy for its obesity drug in Europe and Britain?

Eli Lilly plans to launch its weight-loss pill in Europe and Britain in the second half of 2026 or early 2027, targeting the out-of-pocket telehealth market—as it has done in the U.S.—by partnering with telehealth companies, e-commerce platforms, and direct-to-patient channels, since most obesity treatment outside the U.S. is paid for directly by patients rather than public health systems; the company will still pursue public reimbursement where feasible but prioritizes a consumer-focused, commercially driven model built on lessons from its U.S. obesity business development.

Eli Lilly Says Trump Pricing Policy Will Affect Obesity Drug Launches in Europe

Jun 23, 2026

Eli Lilly targets European obesity drug launches by late 2026 via telehealth, citing U.S. pricing policies as a key factor in reimbursement negotiations and market strategy.

reuters

2026-06-23

Eli Lilly Says Trump Pricing Policy Will Affect Obesity Drug Launches in Europe

Eli Lilly Says Trump Pricing Policy Will Affect Obesity Drug Launches in Europe

FAQ